Your browser doesn't support javascript.
loading
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
Goodall, Ruth L; Meredith, Sarah K; Nunn, Andrew J; Bayissa, Adamu; Bhatnagar, Anuj K; Bronson, Gay; Chiang, Chen-Yuan; Conradie, Francesca; Gurumurthy, Meera; Kirenga, Bruce; Kiria, Nana; Meressa, Daniel; Moodliar, Ronelle; Narendran, Gopalan; Ngubane, Nosipho; Rassool, Mohammed; Sanders, Karen; Solanki, Rajesh; Squire, S Bertel; Torrea, Gabriela; Tsogt, Bazarragchaa; Tudor, Elena; Van Deun, Armand; Rusen, I D.
Afiliação
  • Goodall RL; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK. Electronic address: r.goodall@ucl.ac.uk.
  • Meredith SK; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK.
  • Nunn AJ; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK.
  • Bayissa A; Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
  • Bhatnagar AK; Rajan Babu Institute for Pulmonary Medicine & Tuberculosis, Delhi, India.
  • Bronson G; Vital Strategies, New York, NY, USA.
  • Chiang CY; Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; International Union against Tuberculosis and Lung Disease, Paris, France.
  • Conradie F; Empilweni TB Hospital, Eastern Cape, South Africa.
  • Gurumurthy M; Vital Strategies, Singapore.
  • Kirenga B; Makerere University Lung Institute, Mulago Hospital, Kampala, Uganda.
  • Kiria N; National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
  • Meressa D; St Peter's Tuberculosis Specialized Hospital and Global Health Committee, Addis Ababa, Ethiopia.
  • Moodliar R; Tuberculosis & HIV Investigative, Doris Goodwin Hospital, Pietermaritzburg, South Africa.
  • Narendran G; National Institute for Research in Tuberculosis, Chennai, India.
  • Ngubane N; King Dinuzulu Hospital Complex, Durban, South Africa.
  • Rassool M; Clinical HIV Research Unit, Helen Joseph Hospital, Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa.
  • Sanders K; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK.
  • Solanki R; B J Medical College, Ahmedabad, India.
  • Squire SB; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Torrea G; Institute of Tropical Medicine, Antwerp, Belgium.
  • Tsogt B; Mongolian Tuberculosis Coalition, Ulaanbaatar, Mongolia.
  • Tudor E; Institute of Phthisiopneumology Chiril Draganiuc, Chisinau, Moldova.
  • Van Deun A; Institute of Tropical Medicine, Antwerp, Belgium.
  • Rusen ID; Vital Strategies, New York, NY, USA.
Lancet ; 400(10366): 1858-1868, 2022 11 26.
Article em En | MEDLINE | ID: mdl-36368336
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Tuberculose Resistente a Múltiplos Medicamentos Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Tuberculose Resistente a Múltiplos Medicamentos Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article